Medigene Future Growth
Future criteria checks 1/6
Medigene's earnings are forecast to decline at 4.1% per annum while its annual revenue is expected to grow at 16.1% per year. EPS is expected to grow by 11.7% per annum.
Key information
-4.1%
Earnings growth rate
11.7%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 16.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 16 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 16 | -12 | N/A | N/A | 1 |
| 12/31/2025 | 10 | -14 | N/A | N/A | 1 |
| 12/31/2024 | 11 | -12 | N/A | N/A | 1 |
| 6/30/2024 | 7 | -16 | -15 | -14 | N/A |
| 3/31/2024 | 7 | -16 | -15 | -15 | N/A |
| 12/31/2023 | 6 | -16 | -16 | -15 | N/A |
| 9/30/2023 | 8 | -23 | -15 | -14 | N/A |
| 6/30/2023 | 9 | -29 | -15 | -13 | N/A |
| 3/31/2023 | 20 | -19 | -2 | -1 | N/A |
| 12/31/2022 | 31 | -8 | 11 | 12 | N/A |
| 9/30/2022 | 31 | 1 | 12 | 13 | N/A |
| 6/30/2022 | 31 | 10 | 14 | 14 | N/A |
| 3/31/2022 | 21 | 0 | 1 | 2 | N/A |
| 12/31/2021 | 10 | -10 | -11 | -11 | N/A |
| 9/30/2021 | 10 | -16 | -14 | -14 | N/A |
| 6/30/2021 | 9 | -22 | -17 | -17 | N/A |
| 3/31/2021 | 8 | -25 | -21 | -21 | N/A |
| 12/31/2020 | 8 | -29 | -24 | -25 | N/A |
| 9/30/2020 | 9 | -25 | N/A | N/A | N/A |
| 6/30/2020 | 9 | -23 | -26 | -27 | N/A |
| 3/31/2020 | 10 | -21 | N/A | N/A | N/A |
| 12/31/2019 | 11 | -20 | -17 | -16 | N/A |
| 9/30/2019 | 9 | -23 | N/A | N/A | N/A |
| 6/30/2019 | 9 | -23 | -15 | -14 | N/A |
| 3/31/2019 | 8 | -19 | N/A | N/A | N/A |
| 12/31/2018 | 8 | -21 | -10 | -10 | N/A |
| 9/30/2018 | 8 | -18 | N/A | N/A | N/A |
| 6/30/2018 | 8 | -16 | -9 | -11 | N/A |
| 3/31/2018 | 8 | -16 | N/A | N/A | N/A |
| 12/31/2017 | 8 | -16 | N/A | -21 | N/A |
| 9/30/2017 | 8 | -14 | N/A | N/A | N/A |
| 6/30/2017 | 8 | -17 | N/A | -7 | N/A |
| 3/31/2017 | 8 | -12 | N/A | N/A | N/A |
| 12/31/2016 | 7 | -9 | N/A | -4 | N/A |
| 9/30/2016 | 6 | -8 | N/A | N/A | N/A |
| 6/30/2016 | 7 | -7 | N/A | -14 | N/A |
| 3/31/2016 | 7 | -11 | N/A | N/A | N/A |
| 12/31/2015 | 7 | -13 | N/A | -11 | N/A |
| 9/30/2015 | 11 | -11 | N/A | -9 | N/A |
| 6/30/2015 | 11 | -9 | N/A | -8 | N/A |
| 3/31/2015 | 13 | -7 | N/A | -8 | N/A |
| 12/31/2014 | 13 | -6 | N/A | -9 | N/A |
| 9/30/2014 | 10 | -8 | N/A | -9 | N/A |
| 6/30/2014 | 9 | -7 | N/A | -10 | N/A |
| 3/31/2014 | 8 | -9 | N/A | -12 | N/A |
| 12/31/2013 | 8 | -10 | N/A | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDG1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDG1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDG1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MDG1's revenue (16.1% per year) is forecast to grow faster than the Swiss market (4.3% per year).
High Growth Revenue: MDG1's revenue (16.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDG1's Return on Equity is forecast to be high in 3 years time